NASDAQ: NOVNNovan Inc Stock
$1.11-0.02 (-1.77%)
Updated Mar 29, 2023
NOVN Price
$1.11
Fair Value Price
$1.72
Market Cap
$27.15M
52 Week Low
$0.79
52 Week High
$4.09
P/E
-0.6x
P/B
4.02x
P/S
3.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.86M
Earnings
-$36.52M
Gross Margin
69.3%
Operating Margin
-253.65%
Profit Margin
-263.6%
Debt to Equity
11.32
Operating Cash Flow
-$29M
Beta
0.93
Next Earnings
Mar 30, 2023
Ex-Dividend
N/A
Next Dividend
N/A
NOVN Overview
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NOVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NOVN ($1.11) is undervalued by 35.44% relative to our estimate of its Fair Value price of $1.72 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NOVN ($1.11) is significantly undervalued by 35.44% relative to our estimate of its Fair Value price of $1.72 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NOVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NOVN due diligence checks available for Premium users.
Be the first to know about important NOVN news, forecast changes, insider trades & much more!
NOVN News
Valuation
NOVN fair value
Fair Value of NOVN stock based on Discounted Cash Flow (DCF)
Price
$1.11
Fair Value
$1.72
Undervalued by
35.44%
NOVN ($1.11) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NOVN ($1.11) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NOVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NOVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.6x
Industry
18.17x
Market
21.81x
NOVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.02x
Industry
4.92x
NOVN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NOVN's financial health
Profit margin
Revenue
$5.1M
Net Income
-$6.0M
Profit Margin
-117.9%
NOVN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NOVN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$83.3M
Liabilities
$76.5M
Debt to equity
11.32
NOVN's short-term liabilities ($35.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NOVN's long-term liabilities ($40.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NOVN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NOVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.4M
Investing
-$3.0M
Financing
-$10.0M
NOVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NOVN vs Biotech Stocks
Novan Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.